Anixa Biosciences, Inc. (ANIX) Financial Statements (2024 and earlier)

Company Profile

Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250
SAN JOSE, CA 95118
State of Incorp. DE
Fiscal Year End October 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

1/31/2024
Q1
10/31/2023
Q4
7/31/2023
Q3
4/30/2023
Q2
1/31/2023
Q1
10/31/2022
Q4
7/31/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments23,84425,53426,97627,70229,68731,664
Cash and cash equivalents9153,1985,6209,79012,36024,254
Short-term investments22,92922,33621,35617,91217,3277,410
Receivables270334256147  
Other undisclosed current assets1,242532178256513676
Total current assets:25,35626,40027,41028,10530,20032,340
Noncurrent Assets
Operating lease, right-of-use asset166178189201212223
Total noncurrent assets:166178189201212223
TOTAL ASSETS:25,52226,57827,59928,30630,41232,563
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,9761,8061,4881,1851,9911,425
Accounts payable20694195110265227
Accrued liabilities1,7701,7121,2931,0751,7261,198
Other undisclosed current liabilities525149474644
Total current liabilities:2,0281,8571,5371,2322,0371,469
Noncurrent Liabilities
Long-term debt and lease obligation:      187
Liabilities, other than long-term debt123136149162175 
Operating lease, liability123136149162175187
Other undisclosed noncurrent liabilities      (187)
Total noncurrent liabilities:123136149162175187
Total liabilities:2,1511,9931,6861,3942,2121,656
Equity
Equity, attributable to parent24,33725,52026,81127,79129,04731,701
Common stock311310310309309307
Additional paid in capital252,222250,716249,496248,189247,123246,303
Accumulated deficit(228,196)(225,506)(222,995)(220,707)(218,385)(214,909)
Equity, attributable to noncontrolling interest(966)(935)(898)(879)(847)(794)
Total equity:23,37124,58525,91326,91228,20030,907
TOTAL LIABILITIES AND EQUITY:25,52226,57827,59928,30630,41232,563

Income Statement (P&L) ($ in thousands)

1/31/2024
Q1
10/31/2023
Q4
7/31/2023
Q3
4/30/2023
Q2
1/31/2023
Q1
10/31/2022
Q4
7/31/2022
Q3
Revenues   210   
Cost of revenue(1,615)(1,088)(1,159)(1,068)(6,477)(86)
Gross profit:(1,615)(1,088)(949)(1,068)(6,477)(86)
Operating expenses(1,436)(1,756)(1,611)(1,488)2,868(2,711)
Operating loss:(3,051)(2,844)(2,560)(2,556)(3,609)(2,797)
Loss from continuing operations:(3,051)(2,844)(2,560)(2,556)(3,609)(2,797)
Loss before gain (loss) on sale of properties:(2,797)
Other undisclosed net income3302962532028022
Net loss:(2,721)(2,548)(2,307)(2,354)(3,529)(2,775)
Net income attributable to noncontrolling interest313719325329
Net loss available to common stockholders, diluted:(2,690)(2,511)(2,288)(2,322)(3,476)(2,746)

Comprehensive Income ($ in thousands)

1/31/2024
Q1
10/31/2023
Q4
7/31/2023
Q3
4/30/2023
Q2
1/31/2023
Q1
10/31/2022
Q4
7/31/2022
Q3
Net loss:(2,721)(2,548)(2,307)(2,354)(3,529)(2,775)
Comprehensive loss:(2,721)(2,548)(2,307)(2,354)(3,529)(2,775)
Comprehensive income, net of tax, attributable to noncontrolling interest313719325329
Comprehensive loss, net of tax, attributable to parent:(2,690)(2,511)(2,288)(2,322)(3,476)(2,746)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: